Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · Real-Time Price · USD

27.81

-1.95 (-6.55%)

At close: Oct 29, 2025, 4:00 PM EDT

27.82

+0.01 (0.04%)

After-hours: Oct 29, 2025, 4:40 PM EDT

Janux Therapeutics Employees

Janux Therapeutics had 81 employees as of December 31, 2024. The number of employees increased by 17 or 26.56% compared to the previous year.

Employees

81

Change (1Y)

17

Growth (1Y)

26.56%

Revenue / Employee

$5,420

Profits / Employee

-$1,304,210

Market Cap

1.67B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	81	17	26.56%
Dec 31, 2023	64	4	6.67%
Dec 31, 2022	60	27	81.82%
Dec 31, 2021	33	21	175.00%
Dec 31, 2020	12	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

JANX News

2 months ago - Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
3 months ago - Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Business Wire
3 months ago - Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash - Seeking Alpha
3 months ago - Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day - Business Wire
3 months ago - Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 - Business Wire
5 months ago - Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer - Business Wire
6 months ago - Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
6 months ago - Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates - Business Wire